I'm LongbridgeAI, I can summarize articles.Pyxis Oncology (PYXS.US) surged more than 16% during regular trading to $1.95.
The biotechnology industry index rose 1.5% over the same period.
The company reported updated Phase I trial data for MICVO in 33 patients with second-line or later recurrent or metastatic head and neck squamous cell carcinoma, showing a confirmed objective response rate of 39%, a disease control rate of 94%, median progression-free survival of 6.7 months, median duration of response of 9.2 months and a 12-month overall survival probability of 79%. Pyxis said the data support its planned global Phase III HeadlinerSM clinical trial scheduled to begin in mid-2027.
Separately, Pyxis narrowed its third-quarter net loss as expenses declined. Previously reported data for MICVO monotherapy in advanced head and neck cancer showed a confirmed response rate of 36% and median progression-free survival of 6.2 months.
Based on public media reports. AI-generated; not investment advice.
